{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:40:21Z","timestamp":1791834021582,"version":"4.3.4"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006520","name":"Edwards Lifesciences","doi-asserted-by":"publisher","award":["K12DA035150"],"award-info":[{"award-number":["K12DA035150"]}],"id":[{"id":"10.13039\/100006520","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.carrev.2025.07.007","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T15:08:35Z","timestamp":1752937715000},"page":"40-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Sex differences in high-potency P2Y12 inhibitors prescription among patients with acute myocardial infarction"],"prefix":"10.1016","volume":"83","author":[{"given":"Hend","family":"Mansoor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remy","family":"Poudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyun","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathie","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Sigal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Tamis-Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinav","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Islam Y.","family":"Elgendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.carrev.2025.07.007_bb0005","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.carrev.2025.07.007_bb0010","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.carrev.2025.07.007_bb0015","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014457","article-title":"Efficacy and safety of high potent P2Y12 inhibitors prasugrel and ticagrelor in patients with coronary heart disease treated with dual antiplatelet therapy: a sex-specific systematic review and meta-analysis","volume":"9","author":"Schreuder","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.carrev.2025.07.007_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2025.04.035","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","author":"Rao","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2025.07.007_bb0025","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2025.07.007_bb0030","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.008125","article-title":"Ticagrelor use in acute myocardial infarction: insights from the national cardiovascular data registry","volume":"7","author":"Basra","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.carrev.2025.07.007_bb0035","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jamainternmed.2018.0783","article-title":"Trends in platelet adenosine diphosphate P2Y12 receptor inhibitor use and adherence among antiplatelet-naive patients after percutaneous coronary intervention, 2008-2016","volume":"178","author":"Dayoub","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.carrev.2025.07.007_bb0040","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.28182","article-title":"Variations in quality of care by sex and social determinants of health among younger adults with acute myocardial infarction in the US and Canada","volume":"4","author":"Raparelli","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.carrev.2025.07.007_bb0045","article-title":"Socioeconomic disparities in the management and outcomes of acute myocardial infarction","author":"Weight","year":"2023","journal-title":"Heart"},{"key":"10.1016\/j.carrev.2025.07.007_bb0050","doi-asserted-by":"crossref","first-page":"E171","DOI":"10.25270\/jic\/21.00055","article-title":"Identifying racial, ethnic, and socioeconomic inequities in the use of novel P2Y12 inhibitors after percutaneous coronary intervention","volume":"34","author":"Nathan","year":"2022","journal-title":"J Invasive Cardiol"},{"key":"10.1016\/j.carrev.2025.07.007_bb0055","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1001\/jama.2022.20149","article-title":"Treatment time and in-hospital mortality among patients with ST-segment elevation myocardial infarction, 2018-2021","volume":"328","author":"Jollis","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.carrev.2025.07.007_bb0060","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCULATIONAHA.123.065512","article-title":"Race-based differences in ST-segment-elevation myocardial infarction process metrics and mortality from 2015 through 2021: an analysis of 178 062 patients From the American Heart Association Get With The Guidelines-Coronary Artery Disease Registry","volume":"148","author":"Osho","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2025.07.007_bb0065","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.121.008612","article-title":"County-level social vulnerability is associated with in-hospital death and major adverse cardiovascular events in patients hospitalized with COVID-19: an analysis of the American Heart Association COVID-19 Cardiovascular Disease Registry","volume":"15","author":"Islam","year":"2022","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.carrev.2025.07.007_bb0070","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.000849","article-title":"Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry","volume":"3","author":"Sherwood","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.carrev.2025.07.007_bb0075","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.119.006275","article-title":"Physician and hospital utilization of P2Y12 inhibitors in ST-segment-elevation myocardial infarction in the United States: a study from the National Cardiovascular Data Registry\u2019s research to practice initiative","volume":"13","author":"Faridi","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.carrev.2025.07.007_bb0080","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jcin.2021.12.033","article-title":"Sex differences in management and outcomes of acute myocardial infarction patients presenting with cardiogenic shock","volume":"15","author":"Elgendy","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2025.07.007_bb0085","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.amjcard.2023.06.036","article-title":"Bleeding and ischemic risk prediction in patients with high bleeding risk (an EVOLVE Short DAPT Analysis)","volume":"207","author":"Mihatov","year":"2023","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.carrev.2025.07.007_bb0090","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.jacc.2023.07.031","article-title":"Comparison of antiplatelet monotherapies after percutaneous coronary intervention according to clinical, ischemic, and bleeding risks","volume":"82","author":"Yang","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2025.07.007_bb0095","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003946","volume":"5","author":"Vora","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.carrev.2025.07.007_bb0100","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.122.012447","article-title":"Sex-specific differences in potent P2Y12 inhibitor use in British Cardiovascular Intervention Society Registry STEMI Patients","volume":"16","author":"Burgess","year":"2023","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2025.07.007_bb0105","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007123","article-title":"Sex differences in treatments, relative survival, and excess mortality following acute myocardial infarction: national cohort study using the SWEDEHEART registry","volume":"6","author":"Alabas","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.carrev.2025.07.007_bb0110","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.020828","article-title":"Racial disparities in adverse cardiovascular outcomes after a myocardial infarction in young or middle-aged patients","volume":"10","author":"Garcia","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.carrev.2025.07.007_bb0115","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/jama.297.10.1063","article-title":"Financial barriers to health care and outcomes after acute myocardial infarction","volume":"297","author":"Rahimi","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.carrev.2025.07.007_bb0120","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.4240","article-title":"Racial disparities in patient characteristics and survival after acute myocardial infarction","volume":"1","author":"Graham","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.carrev.2025.07.007_bb0125","doi-asserted-by":"crossref","first-page":"314","DOI":"10.7326\/0003-4819-150-5-200903030-00007","article-title":"Factors associated with racial differences in myocardial infarction outcomes","volume":"150","author":"Spertus","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.carrev.2025.07.007_bb0130","first-page":"34","article-title":"Measuring community vulnerability to natural and anthropogenic hazards: the Centers for Disease Control and Prevention\u2019s social vulnerability index","volume":"80","author":"Flanagan","year":"2018","journal-title":"J Environ Health"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838925003902?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838925003902?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T05:40:51Z","timestamp":1772775651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838925003902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":26,"alternative-id":["S1553838925003902"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2025.07.007","relation":{},"ISSN":["1553-8389"],"issn-type":[{"value":"1553-8389","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sex differences in high-potency P2Y12 inhibitors prescription among patients with acute myocardial infarction","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2025.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}